Research No Longer Recruiting Patients

The research studies listed below are no longer recruiting patients.

If you have questions about any of the research studies listed below, please leave a voicemail for our research team at 206-320-2200.

OPERA WA21903

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

Sponsor: Roche Gententech

Type of MS: RR

Contact: Yuriko Courtney 206-320-2647

More information

DioGenix Specificity Study
Differential Gene Expression Profiling in the Blood of Patients with Multiple Sclerosis and MS Mimics

Sponsor: DioGenix
Types of MS: RR, SP

--------------------------------------------------------------------------------

DioGenix Steroid Study
DifferTemporal Gene Expression and microRNA Profiling in the Blood of Patients with Demyelinating Disease Treated with Steroids ential Gene Expression Profiling in the Blood of Patients with Multiple Sclerosis and MS Mimics

Sponsor: DioGenix
Types of MS: RR, CIS

CARE-MS Extension

An extension protocol for multiple sclerosis patients who participated in Genzyme-sponsored studies of alemtuzumab.

Sponsor: Genzyme

Type of MS : RR
More Information

Tygris

Tygris: Tysabri global observational program in safety

Sponsor: Biogen
More Information

BG12 Extension

A dose-blind, multicenter, extension study to determine the long-term safety and efficacy of two doses of BG00012 monotherapy in subjects with relapsing-remitting multiple sclerosis

Sponsor: Biogen
More Information

HALT-MS

A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis

Sponsor: NIH

BAF Extension

A dose blinded extension study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis

Sponsor: Novartis

Type of MS : RR

More Information

STRATIFY
JCV antibody program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri: Stratify-2

Sponsor: Biogen
Types of MS : RR
More Information